Barclay’s Alexander Kleban downgraded Smith & Nephew plc (ADR) from Overweight to Equal-Weight while increasing the company’s price target by 0.81 percent.Although the analyst believed the company’s transition to a higher growth platform is “underappreciated” by the general market in conjunction with remaining potential upside from M&A, results continue to disappoint."Additionally, emerging market headwinds should start to dissipate somewhere in H2 and Wound Devices are set for a late 2016-17 product cycle (Renasys re-launch),” stated Kleban.Full